10
39
18
↑10
↓39
—18
Evidence suggests Melatonin maydecreaseDepression.
52 studies (67 claims)
Emerging evidence
Typical effective dose 6 (4–10) mgacross 19 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| Melatonin | No effect - has no antidepressant action | depression | Human | MDD patients | Not specified | Circadian rhythms, melatonin and depression. |
| Melatonin | No effect - has no antidepressant action | depression | Human | MDD patients | Not specified | Circadian rhythms, melatonin and depression. |
| melatonin | No effect - role as an antidepressant has yet to be demonstrated | depression | Human | — | Not specified | Manipulating melatonin in managing mood. |
| melatonin | No effect - role as an antidepressant has yet to be demonstrated | depression | Human | — | Not specified | Manipulating melatonin in managing mood. |
| melatonin | Decreases - alleviate | depression | Human | PD patients | Not specified | Chronotherapies for Parkinson's disease.cited 30× |
| melatonin | Increases - induced improvements | depression | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| exogenous melatonin | Increases - positive effects | depression | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin agonists | Increases - positive effects | depression | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin agonists | Increases - induced improvements | depression | Human | persons with Parkinson's disease (PwP) | Not specified | The multimodal effect of circadian interventions in Parkinson's disease: A narrative review.cited 3× |
| melatonin | Decreases - possible reported antidepressive effect | depression | Human | — | Not mentioned. | Exploring the reasons why melatonin can improve tinnitus.cited 16× |
| melatonin | No effect - has recently seen an unexpected extension of its functional implications toward | depression | HumanAnimal | — | Not available | Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. |
| melatonin | No effect - has recently seen an unexpected extension of its functional implications toward | depression | HumanAnimal | — | Not available | Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. |
| melatonin | Decreases - showed a significant prophylactic effect | depression | Human | — | 0.5-6 mg daily | The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis.cited 43× |
| melatonin | Decreases - found a significant treatment effect | depression | Human | — | 0.5-6 mg daily | The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis.cited 43× |
| melatonin | Decreases - showed an improvement | depression scores | Human | patients | 0.5-6 mg daily | The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis.cited 43× |
| melatonin | Decreases - showed an improvement | depression scores | Human | — | 0.5-6 mg daily | The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis.cited 43× |
| melatonin | No effect - no significant difference | depression scores | Human | — | 0.5-6 mg daily | The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis.cited 43× |
| melatonin | Decreases - has a preventive effect | depression | Human | patients after acute coronary syndrome | 25 mg melatonin. | The effect of MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome (MEDACIS): study protocol for a randomized controlled trial.cited 16× |
| melatonin | No effect - showed no prophylactic antidepressant effect | depression | Human | patients following acute coronary syndrome | 25 mg administered 1 hour before bedtime. | The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial.cited 14× |
| melatonin | No effect - no significant intergroup differences were found | Major Depression Inventory (MDI) score | Human | patients following acute coronary syndrome | 25 mg administered 1 hour before bedtime. | The effect of melatonin on depressive symptoms and anxiety in patients after acute coronary syndrome: The MEDACIS randomized clinical trial.cited 14× |
| melatonin | No effect - No significant changes were observed in | depression | Human | menopausal women | 1 mg to 5 mg (varied by study). | Effects of exogenous melatonin on sleep quality and menopausal symptoms in menopausal women: a systematic review and meta-analysis of randomized controlled trials.cited 9× |
| melatonin (MLT) | Decreases - eased | depression | Human | patients who received administration for more than 14 days | — | Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials.cited 10× |
| melatonin (MLT) | Decreases - eased | depression | Human | patients who underwent surgery | — | Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials.cited 10× |
| melatonin | Decreases - efficacious in lowering | depression | Human | — | — | Sleep, Dietary Melatonin Supplementation, and COVID-19.cited 5× |
| melatonin | No effect - effect on | depression | Human | participants | 25 mg melatonin administered rectally daily. | Effect of melatonin in patients with low anterior resection syndrome (MELLARS): a study protocol for a randomised, placebo-controlled, crossover trial.cited 2× |
| melatonin | No effect - did not find substantial evidence supporting the use | depression | Human | breast cancer patients | 6 mg daily | Melatonin Aids in Treating Mood and Sleep Problems Resulting from Hormonal Therapy in Breast Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. |
| melatonin | No effect - no significant improvements | depression severity | Human | breast cancer patients undergoing hormone therapy | 6 mg daily | Melatonin Aids in Treating Mood and Sleep Problems Resulting from Hormonal Therapy in Breast Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. |
| melatonin | No effect - did not demonstrate significant effects | depression | Human | hemodialysis patients | 3 mg daily melatonin. | Role of Melatonin as an Adjunctive Treatment for Depression and Cognitive Impairment in Hemodialysis Patients: A Randomized, Double-Blind Clinical Trial. |
| melatonin | Decreases - reduced | depression | Human | human participants | — | Differential Function of Melatonin MT |
| melatonin (3-6 mg/d) | Decreases - had significantly been effective | pain, sleep, daytime fatigue, and depression | Human | subjects affected from FMS | 25 mg/d (single daily dose). | Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study.cited 17× |
| melatonin (5 mg) | No effect - no statistically significant between-group differences | Personal Health Questionnaire Depression Scale (PHQ-8) | Human | males 18 years of age and older in recovery from substance use | 5 mg melatonin daily. | The Effect of Melatonin Upon Postacute Withdrawal Among Males in a Residential Treatment Program (M-PAWS): A Randomized, Double-blind, Placebo-controlled Trial.cited 3× |
| melatonin | No effect - not significantly different | Quick Inventory of Depression Symptomatology Clinician Version-16 (QIDS-C16) scores | Human | adult bipolar patients aged 18-65 years | Modified release melatonin (specific dosage not mentioned). | Melatonin In Acute Mania Investigation (MIAMI-UK). A randomized controlled trial of add-on melatonin in bipolar disorder.cited 8× |
| Melatonin | Decreases - could be used as an adjuvant treatment | symptoms of insomnia associated with depression | Human | — | Not specified | Biological rhythms and chronotherapeutics in depression.cited 45× |
| exogenous melatonin (5mg) | Decreases - significantly reduced | depression scores | Human | DSPS patients with depressive symptoms (Group I) | 5mg melatonin | Antidepressant action of melatonin in the treatment of Delayed Sleep Phase Syndrome.cited 56× |
| Buspirone and melatonin | Decreases - supporting the potential use for treating | depression | Human | — | Not specified | Buspirone: Back to the Future.cited 39× |
| slow-release melatonin (6 mg) | Increases - showed significant improvements | depression and sleep | Human | participants with a Diagnostic and Statistical Manual of Mental Disorders (fourth edition) diagnosis of MDD and early-morning waking | 6 mg slow-release melatonin at bedtime. | A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.cited 48× |
| slow-release melatonin (6 mg) | No effect - was not specific to | improvements in depression and sleep | Human | participants with a Diagnostic and Statistical Manual of Mental Disorders (fourth edition) diagnosis of MDD and early-morning waking | 6 mg slow-release melatonin at bedtime. | A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.cited 48× |
| melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) | No effect - have recently become available for the treatment of | insomnia, depression and circadian rhythms sleep-wake disorders | Human | — | Not specified | Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.cited 75× |
| combination of agmatine and melatonin | No effect - improves | stress-induced depression | Animal | mice | Agmatine (1 mg/kg/day), melatonin (10 mg/kg/day), and fluoxetine (10 mg/kg/day). | Study of the Antidepressant Effects of the Combination of Agmatine and Melatonin Following Restraint Stress in Mice: the Role of Oxidative Factors. |
| 3 mg oral melatonin treatment daily | Decreases - exhibited a significantly lower score | Hamilton depression scale (HAMD) | Human | healthy perimenopausal women | 3 mg oral melatonin daily. | Influence of Melatonin Treatment on Emotion, Sleep, and Life Quality in Perimenopausal Women: A Clinical Study.cited 1× |
| decreased melatonin | Increases - is linked to | depression and depression-associated disorders | Human | — | Not mentioned | Breastfeeding and the gut-brain axis: is there a role for melatonin?cited 28× |
| fluoxetine (20 mg in the morning) and melatonin (5 mg in the evening) | Decreases - comparable and statistically significant reduction | level of anxiety and depression | Human | overweight postmenopausal women, aged 54 - 65 years, with increased appetite | 5 mg melatonin in the evening, daily. | Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women.cited 38× |
| melatonin alone | Increases - significant improvements | Beck Depression Inventory (BDI) | Human | patients with unilateral acute idiopathic tinnitus developed within 3months | Not specified | Intratympanic dexamethasone plus melatonin versus melatonin only in the treatment of unilateral acute idiopathic tinnitus.cited 8× |
| melatonin and IT dexamethazone | Increases - significant improvements | Beck Depression Inventory (BDI) | Human | patients with unilateral acute idiopathic tinnitus developed within 3months | Not specified | Intratympanic dexamethasone plus melatonin versus melatonin only in the treatment of unilateral acute idiopathic tinnitus.cited 8× |
| melatonin supplementation | Decreases - decreased | anxiety on the Hospital Anxiety Depression Scale | Human | patients with traumatic brain injury (TBI) | 2 mg prolonged-release melatonin (Circadin®) nightly, 2 hours before bedtime. | Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial.cited 88× |
| melatonin supplementation | Decreases - significantly reduced | Beck Depression Inventory (BDI) | Human | patients with PD | 10 mg melatonin (two 5 mg capsules) once daily before bedtime. | Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial.cited 53× |
| melatonin supplementation | Decreases - significantly decreased | Beck Depression Inventory index | Human | patients under methadone maintenance treatment (MMT) | — | The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment.cited 35× |
| melatonin supplementation | Decreases - significantly decreased | Beck Depression Inventory index | Human | women with polycystic ovary syndrome (PCOS) | 10 mg melatonin (two 5 mg capsules) once daily before bedtime. | Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.cited 58× |
| melatonin supplementation | Decreases - significantly decreased | Beck Depression Inventory index | Human | diabetic hemodialysis (HD) patients | 2 x 5mg/day (10mg total daily dose), taken 1 hour before bedtime. | The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 39× |
| melatonin supplementation | Decreases - has a decreasing effect on depression | depression | Human | age more than 65 years | — | Effects of melatonin supplementation on BDNF concentrations and depression: A systematic review and meta-analysis of randomized controlled trials.cited 11× |
| melatonin supplementation | Decreases - has a decreasing effect on depression | depression | Human | — | — | Effects of melatonin supplementation on BDNF concentrations and depression: A systematic review and meta-analysis of randomized controlled trials.cited 11× |
| melatonin supplementation | Decreases - has a decreasing effect on depression | depression | Human | — | — | Effects of melatonin supplementation on BDNF concentrations and depression: A systematic review and meta-analysis of randomized controlled trials.cited 11× |
| melatonin supplementation | Decreases - improved depression by decreasing the score | depression score | Human | adults | — | Effects of melatonin supplementation on BDNF concentrations and depression: A systematic review and meta-analysis of randomized controlled trials.cited 11× |
| melatonin intake | Decreases - significantly reduced | menopausal depression | Human | menopausal women | Not specified | Effects of melatonin intake on depression and anxiety in postmenopausal women: a systematic review and meta-analysis of randomised controlled trials.cited 2× |
| an abnormal melatonin rhythm | Increases - may contribute to | depression and insomnia | Human | — | Not specified | A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. |
| an abnormal melatonin rhythm | Increases - may contribute to | depression and insomnia | Human | — | Not specified | A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. |
| exogenous oral melatonin | Decreases - showed a significant improvement | scores of Hamilton Depression Rating Scale (HDRS) | Human | HD patients | — | Study of Exogenous Melatonin as a Treatment Modality for Sleep and Psychiatric Disorders in Hemodialysis Patients.cited 3× |
| Sildenafil plus Melatonin | Decreases - reduce | depression severity | Human | women with PCOS who undergoing Metformin | Not specified in the abstract. | Improved psychosexual wellbeing with administration of combined Sildenafil plus Melatonin compared than either drug alone in management of women with polycystic ovarian syndrome: a 3-month randomized clinical study. |
| Sildenafil plus Melatonin | Decreases - statistically significant improvement was found | severity of depression | Human | women with PCOS undergoing Metformin | Not specified in the abstract. | Improved psychosexual wellbeing with administration of combined Sildenafil plus Melatonin compared than either drug alone in management of women with polycystic ovarian syndrome: a 3-month randomized clinical study. |
| melatonin intervention | No effect - shows no substantial impact | depression | Human | patients after laparoscopic cholecystectomy | Not specified in the abstract. | The Influence of Melatonin on Sleep Quality After Laparoscopic Cholecystectomy: A Meta-Analysis of Randomized Controlled Trials.cited 7× |
| natural compound, composed of melatonin (1,5 mg) and cannabis extracts (2.5 mg CBD) | Decreases - evidenced reduction | mood alterations, including anxiety, panic, paranoia, depression | Human | patients with sleep disorders | 1.5 mg melatonin and 2.5 mg CBD (20 drops sublingually overnight). | Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts.cited 3× |
| 3 mg oral melatonin | No effect - no significant differences | measures of depression | Human | postmenopausal breast cancer survivors | 3 mg oral melatonin daily | A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes.cited 88× |